Scarica l'app Stockscreener
18.05
3.80%
0.66
Dopo l'orario di chiusura:
18.27
0.22
+1.22%
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Vor Biopharma (VOR) upgraded to buy: Here's why - msn.com
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - marketbeat.com
Wall Street analysts predict a 107.82% upside in Vor Biopharma (VOR): Here's what you should know - MSN
Jefferies initiates coverage of Vor Biopharma (VOR) with buy recommendation - MSN
Vor Biopharma (VOR) Upgraded to Buy: Here's Why - Yahoo Finance
Wall Street experts anticipate that Vor Biopharma (VOR) could surge by 107.82%: Key Information You Need to Know - bitget.com
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know - Yahoo Finance
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Chen Yu and TCG entities hold 10.5% of Vor Biopharma (NASDAQ: VOR) - Stock Titan
TCG Crossover funds in Vor (VOR) disclose 2,836,539 common shares - Stock Titan
Vor Biopharma (VOR) ownership update shows RA Capital at 19.9% - Stock Titan
9 new Vor Bio hires get stock awards under Nasdaq inducement rule - Stock Titan
Vor Bio announces $75M private placement - MSN
Wedbush Maintains 'Neutral' Rating, Raises Price Target for Vor Biopharma (VOR) to $15 | VOR Stock News - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - marketbeat.com
Jefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-Buy - marketbeat.com
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What's behind the jump in Vor Biopharma stock? - MSN
Jefferies Initiates Coverage on Vor Biopharma (VOR) with a "Buy" Rating | VOR Stock News - GuruFocus
Vor Biopharma, Inc. (VOR) PT Lowered to $48 at Jefferies - StreetInsider
Stifel cuts Vor Biopharma stock price target on financing assumptions - Investing.com
Stifel cuts Vor Biopharma stock price target on financing assumptions By Investing.com - Investing.com Australia
Vor Biopharma, Inc. (VOR) PT Lowered to $40 at Stifel - StreetInsider
Vor Bio Announces $75 Million Private Placement with TCGX - marketscreener.com
Risk Check: What are Vor Biopharma Incs technical support levels2026 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Vor Bio Annual Report 2025: Telitacicept Global Development Strategy, Regulatory Overview, and Summary Risk Factors - Minichart
Jefferies Financial Group Initiates Coverage on Vor Biopharma (NASDAQ:VOR) - marketbeat.com
Vor Biopharma Q4 profit tops estimates on warrant fair value gain - TradingView
Vor Biopharma (NASDAQ: VOR) secures $75M to fund autoimmune pipeline - Stock Titan
Vor 10-K: $696.0M Net Loss, Operating Expenses $371.6M; Cash Runway Into Early 2029 - TradingView
VOR: 2025 saw a $696M net loss, major restructuring, and a strategic shift to autoimmune therapies - TradingView
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Baird Upgrades Vor Biopharma (VOR) - MSN
Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot - Investing.com Canada
Jefferies initiates Vor Biopharma stock with buy rating on autoimmune pivot By Investing.com - Investing.com South Africa
Jefferies Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
Vor Biopharma Shares Climb 6.4% Premarket Aft - Moomoo
Vor Biopharma Announces $75 Million Private Placement Financing - TipRanks
What's Behind The Jump In Vor Biopharma Stock? - Benzinga
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Highe - Benzinga
Vor Biopharma Raises $75 Million in Private Placement With TCGX, Adds Registration Rights - TradingView
Vor Bio announces $75 million private placement with TCGX - MarketScreener
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
Vor Biopharma Inc. announced that it expects to receive $74.999996 million in funding from TCG Crossover Management, LLC - marketscreener.com
Profit Recap: What are analysts price targets for Vor Biopharma IncQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):